Miraculins Reports on Positive Results as the First Pharmacy Pilot for the Scout DS(R) Diabetes Screening Kiosk Nears Completion - Seite 3

• 18% indicated they were smokers* and would be candidates for government reimbursable smoking cessation programs provided in pharmacy, which the Ontario Government pays up to $125 per qualifying patient;
• 52% indicated they were overweight* and would be candidates for supplements, vitamins, and other related products;
• 16% came into the pharmacy specifically for a Scout DS^® screen, which can result in pharmacy revenue through convenience purchases while that customer is in-store;
• 97% said they would recommend a Scout DS^® screening to family or friends, underscoring significant word-of-mouth potential to increase store traffic;
• 99% planned to see their doctor and make changes to their diet/lifestyles if their Scout DS^® scores were elevated, suggesting that Scout DS^® can be a tipping point for personal action.

There are over 9,000 pharmacies in Canada comprised of national chains and independent brands. Combined with the Canadian Pharmacists Association's own advocacy for pharmacists to take on an increased role in diabetes screening as part of their daily practice,³ Miraculins believes that its Scout DS^® diabetes screening and consumer survey kiosks could help pharmacies play a greater role in diabetes risk assessment, education and awareness, while identifying actionable pathways to increase related in-store revenues and providing enhanced service to customers.

(1) Smart Retailing RX: The Full Value of a Diabetes Patient (February 6, 2012); (2) Centers for Disease Control and Prevention: National Diabetes Statistics Report (2014); (3) Canadian Pharmacists Association: Diabetes Strategy for Pharmacists (2013) *Designates risk factor for diabetes

About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company's Scout DS^® diabetes screening device is the first non-invasive diabetes testing system designed to provide a highly sensitive and convenient method for measuring diabetes related biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout DS^® test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world. The Company's PreVu^® POC Test is a revolutionary new coronary artery disease risk assessment technology that measures cholesterol levels in a patient's skin non-invasively, painlessly and without the need for fasting. For more information visit www.miraculins.com.